Using DigiWest protein profiling to uncover mechanisms of cancer therapy resistance

Two publications provide new insights

Scientists from the NMI Natural and Medical Sciences Institute at the University of Tübingen, a private research foundation dedicated to applied and translational research, and of contract research provider NMI TT Pharmaservices, announced two publications that help uncover mechanisms of resistance to specific cancer treatments, by successfully employing their proprietary DigiWest multiplex protein profiling technology.

Quelle: IDW Informationsdienst Wissenschaft